JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Inicio・Lista de Acciones・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Cerrado

SectorSanidad

24.25 -3.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.9

Máximo

25.14

Métricas clave
By Trading Economics
Ingresos	-10M -67M
Margen de beneficios	-7,753.425
Empleados	186
EBITDA	-9.8M -73M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+116.95% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	260M 1.8B
Apertura anterior	27.79
Cierre anterior	24.25

Noticias sobre sentimiento de mercado

By Acuity

50%

152 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

18.91 / 20.63 Soporte y Resistencia

Celldex Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 feb 2026, 23:11 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Ganancias

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Adquisiciones, fusiones, absorciones

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Charlas de Mercado

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Ganancias

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Ganancias

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Ganancias

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Ganancias

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Ganancias

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Ganancias

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Charlas de Mercado

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc previsión

Precio Objetivo

By TipRanks

116.95% repunte

Estimación a 12 Meses

Media 53.5 USD 116.95%

Máximo 90 USD

Mínimo 24 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.91 / 20.63Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

152 / 352 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.